[PDF] Top 20 Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Has 10000 "Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy" found on our website. Below are the top 20 most common "Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy".
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
... many patients in our cohort received ...to docetaxel based chemotherapy in Europe and United ...with docetaxel based ...Japanese patients [30]. Finally, most ... See full document
8
Prognostic Factors for Overall Survival and Risk Stratification of Prostate Cancer Patients with Biochemical Failure
... into prognostic groups according to different factors known to affect prostate cancer ...Pretreatment risk stratification also plays an important role in the selection and ... See full document
135
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
... Armstrong risk classification (ARC), which classifies CRPC patients into 3 groups ac- cording to 4 risk factors, including visceral metastases, bone scan progression, significant pain, and ... See full document
7
Prognostic and predictive clinical factors in patients with metastatic castration resistant prostate cancer treated with cabazitaxel
... Prognostic factors correlate with outcome independent of treatment ...Predictive factors inform on the probability of response to a treatment and therefore are more useful in helping clinicians ... See full document
17
A prognostic model for stratifying clinical outcomes in chemotherapy naive metastatic castration resistant prostate cancer patients treated with abiraterone acetate
... a prognostic index including six risk factors (RFs) (unfavourable ECOG performance status [PS], presence of liver metastases, short response to luteinizing hormone- releasing hormone [LHRH] ... See full document
13
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
... of prostate cancer are vital for informing trial interpretations, as they provide key insights into pa- tients’ symptoms and treatment response ...with prostate cancer face issues that differ ... See full document
10
A prognostic model for stratifying clinical outcomes in chemotherapy naive metastatic castration resistant prostate cancer patients treated with abiraterone acetate
... six risk factors (RFs) linked to poor survival: Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, liver metastases, time from initiation of androgen- deprivation therapy (ADT) to ... See full document
6
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration Resistant Prostate Cancer
... in patients with mCRPC who received first-line DTX or post-docetaxel ...of docetaxel-based therapy and ...after chemotherapy. PSA cannot Table 6. Associated Baseline Factors of ... See full document
9
Prognostic and predictive clinical factors in patients with metastatic castration resistant prostate cancer treated with cabazitaxel
... of patients enrolled in a prospective study. The small number of patients included in this study could limit its statisti- cal power to detect smaller ...a prognostic factor, but could not be ... See full document
8
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
... with chemotherapy ver- sus placebo and was strongly associated with PSA declines (Prentice criterion ...significant prognostic informa- tion for mCRPC patients, they are not always a surrogate for ... See full document
9
Analyze of Risk Factors Affecting the Outcomes of Docetaxel-prednisone Combination in the Treatment of Metastatic Castration-resistant Prostate Cancer
... of docetaxel re-treatment in docetaxel- pretreated CRPC patients, the authors showed that docetaxel re-treatment preserves antitumor activity and is well tolerated in a selected population of ... See full document
8
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
... Clinical Cancer Research) encompass- ing a wide range of disease ...and prognostic factors used for stratification at ran- ...higher risk of death from coexisting conditions and a rela- ... See full document
13
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
... the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on a 62.. demonstrated survival benefit and a favorable tolerability profile in both t[r] ... See full document
26
Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
... suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients 20. (PTS)[r] ... See full document
23
Monitoring dynamic cytotoxic chemotherapy response in castration resistant prostate cancer using plasma cell free DNA (cfDNA)
... Surprisingly, the decline in long LINE1 in our case study coincided with elevated allele frequency of mutant AR. These results suggest that chemotherapy affected cfDNA derived from the tumor differently than from ... See full document
7
Targeted α-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
... of patients Ac-225-PSMA-617 will ...specific prostate cancer subtypes, such as those with DNA repair defects, are more sensitive to selective tumor cell kill by alpha-particle emitting ... See full document
6
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
... 25 patients were treated with ...25 patients received all six injec- tions of ...in patients with VAS ,4 vs ...a prognostic factor of survival (HR = ... See full document
5
ECF chemotherapy for liver metastases due to castration resistant prostate cancer
... databases. Patients treated for other cancer types, including small cell carcinoma of the prostate and prostate cancers with neuroendocrine features, were ... See full document
5
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
... score performed better than cell count-based clinical pa- rameters in both validation datasets (Tables 3 and 4), suggesting that cell component change was only one fac- tor contributing to the patients ’ ... See full document
15
Bevacizumab induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature
... Before the emergency operation, septic shock was recog- nized, and after the operation, in addition, she developed disseminated intravascular coagulation and oliguria due to acute renal failure. We used continuous venous ... See full document
6
Related subjects